Sylvia S Gayle's research while affiliated with Emory University and other places

Publications (3)

Article
Full-text available
The standard targeted therapy for HER2-overexpressing breast cancer is the HER2 monoclonal antibody, trastuzumab. Although effective, many patients eventually develop trastuzumab resistance. The dual EGFR/HER2 small molecule tyrosine kinase inhibitor lapatinib is approved for use in trastuzumab-refractory metastatic HER2-positive breast cancer. How...
Article
Background: Approximately 20% to 30% of metastatic breast cancers overexpress the HER2 receptor tyrosine kinase. The standard front-line therapy for HER2-overexpressing breast cancer is the HER2 monoclonal antibody trastuzumab. However, for patients whose disease progresses on trastuzumab-based therapy, the dual EGFR/HER2 small-molecule tyrosine ki...
Article
Lapatinib, a dual EGFR/HER2 kinase inhibitor, is approved for use in patients with trastuzumab-refractory HER2- overexpressing breast cancer. Increased PI3K signaling has been associated with resistance to trastuzumab, although its role in lapatinib resistance remains unclear. The purpose of the current study was to determine if PI3K/mTOR activity...

Citations

... The reduction in growth rate as an apparent additional feature of MEK inhibition in nonsmall cell lung cancer tumour initiating cells was already mentioned in (Lundholm et al. 2014), but there we did not have any tool to measure it quantitatively. Another example of reduced colony size was reported after combined MEK and EGFR/HER2 inhibition in breast cancer cells (Gayle et al. 2013). The quantitative description was possible to perform when using the software presented here. ...
... However, MK-2206 has not yet been developed further. AKT/mTOR is highly activated in lapatinib-resistant HER2+ breast cancer cells [131]. The mTOR inhibitor INK-128 can restore the sensitivity of lapatinibresistant HER2+ breast cancer cells to TKIs [127]. ...